Workshop speakers

Lina Badimon

Barcelona, Spain

PATHOGENESIS OF ATHEROSCLEROSIS

Microvesicles and endothelial activation

Colin Baigent

Oxford, UK

PREVENTION AND TREATMENT OF CVD

Chronic kidney disease patients

Marianne Benn

Denmark

ADVANCED CLINICAL SEMINARS

Overweight - lifestyle and drugs

Mariette Book

Leiden, The Netherlands

Mariëtte Boon

Leiden, The Netherlands

Rosalind Coleman

North Carolina, USA

Rosalind Colemen

Chapel Hill, USA

ADVANCED CLINICAL SEMINARS

Natural history of NAFLD

Victoria Delgado

Leiden, The Netherlands

JOINT SYMPOSIUM

How to approach a patient with dyslipidemia without apparent CAD (case by Baris Gencer 5 min) What the guideline says

Sven Franque

Antwerp, Belgium

ADVANCED CLINICAL SEMINARS

Emerging clinical trials to combat NAFLD

Elina Ikonen

Helsinki, Finland

METABOLISM OF LIPIDS AND LIPOPROTEINS

Intracellular cholesterol trafficking

Folkert Kuipers

Groningen, The Netherlands

METABOLISM OF LIPIDS AND LIPOPROTEINS

The role of FXR in reverse cholesterol transport

Ulrich Laufs

Leipzig, Germany

ADVANCED CLINICAL SEMINARS

Management of stable coronary heart disease patients

EDUCATIONAL CME ACCREDITED PROGRAMME

When do we need add on therapies to statin?

The Changing Face of HoFH

How did the ESC/EAS guidelines change my practice?

The Changing Face of HoFH

On the horizon: Novel options for the combination of LDL-C lowering therapies

François Mach

Geneva, Switzerland

JOINT SYMPOSIUM

How to approach a patient with dyslipidemia with CAD (case by Anna Lebedeva 5 min) What the guideline says

EDUCATIONAL CME ACCREDITED PROGRAMME

Are the new EAS/ESC lipids goals reachable in clinical practice?

The Changing Face of HoFH

Introduction. Targeting PCSK9: from bench to real world

The Changing Face of HoFH

LDL-C reduction: earlier, lower, better!

The Changing Face of HoFH

LIVE Panel discussion: with a focus on very-high risk patients

The Changing Face of HoFH

Conclusions and take- home messages

The Changing Face of HoFH

New LDL-C goals: Practical implications for the management of patients with residual risk

David Nanchen

Lausanne, Switzerland

ADVANCED CLINICAL SEMINARS

Limited specificity: scores overestimate risk

Børge Nordestgaard

Copenhagen, Denmark

ADVANCED CLINICAL SEMINARS

Limited sensitivity: scores underestimate risk

Yael Nossent

Vienna, Austria

PATHOGENESIS OF ATHEROSCLEROSIS

The multifactorial nature of microRNAs in vascular remodelling

Katariina Öörni

Helsinki, Finland

PATHOGENESIS OF ATHEROSCLEROSIS

LDL aggregation

Elena Osto

Czech Republic

METABOLISM OF LIPIDS AND LIPOPROTEINS

G-protein coupled bile acid receptors

Eva Prescott

Copenhagen, Denmark

ADVANCED CLINICAL SEMINARS

Impact of smoking and psycosocial health

Paolo Raggi

Alberta, Canada

PREVENTION AND TREATMENT OF CVD

Refinement of risk prediction by imaging

Pelin Sahlén

Sweden

PATHOGENESIS OF ATHEROSCLEROSIS

High-resolution regulatory maps connect vascular risk variants to disease-related pathways

Kristina Schoonjans

Lausanne, Switzerland

Bill Sessa

USA

Oliver Soehnlein

Munich, Germany

PATHOGENESIS OF ATHEROSCLEROSIS

Vulnerable plaque: Current concepts in pathophysiology and imaging

Qi Sun

USA

Bart van de Sluis

Groningen, The Netherlands

METABOLISM OF LIPIDS AND LIPOPROTEINS

Role of the retromer COMMD/WASH complex

Cherian Varghese

Geneva, Switzerland

Tobias Walther

USA

METABOLISM OF LIPIDS AND LIPOPROTEINS

Impact of lipid droplets - implications for human disease

Marit Westerterp

Groningen, The Netherlands

PATHOGENESIS OF ATHEROSCLEROSIS

Inflammasome, neutrophil extracellular traps and cholesterol

Stephan Windecker

Switzerland

Christian Wolfrum

Zürich, Switzerland

METABOLISM OF LIPIDS AND LIPOPROTEINS

Whitening of brown adipose tissue - role of the mevalonate pathwa

Jose Luis Zamorano

Spain

PREVENTION AND TREATMENT OF CVD

Acute coronary syndrome patients

Tanja Zeller

Hamburg, Germany

Alma Zernecke

Würzburg, Germany

PATHOGENESIS OF ATHEROSCLEROSIS

Transcriptomic landscape and heterogeneity of macrophages in atherosclerosis.

Francesca Zimetti

Parma, Italy

METABOLISM OF LIPIDS AND LIPOPROTEINS

Lipoprotein transport in the brain